Aurinia Pharmaceuticals (AUPH)
(Delayed Data from NSDQ)
$11.37 USD
-0.06 (-0.52%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $11.36 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum A VGM
Fundamental Charts
About Dividend Yield (TTM)
Aurinia Pharmaceuticals Inc's dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
AUPH 11.37 -0.06(-0.52%)
Will AUPH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AUPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AUPH
Aurinia (AUPH) Upgraded to Buy: Here's What You Should Know
Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates
AUPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options
Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?
Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?
Other News for AUPH
Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade)
Aurinia Pharmaceuticals Reaches Analyst Target Price
Insider Sell: Greg Keenan Sells 20,000 Shares of Aurinia Pharmaceuticals Inc (AUPH)
Aurinia Pharmaceuticals: Strong Financial Performance and Promising Future Justify Buy Rating
AUPH Analyst Rating Update: RBC Capital Raises Price Target | AUPH Stock News